Literature DB >> 12911279

Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission.

Robert D Hollifield1, Laurence S Harbige, Danielle Pham-Dinh, Mohammed K Sharief.   

Abstract

We investigated circulating anti-inflammatory and pro-inflammatory cytokines, and their ex vivo PBMC production in the absence or presence of the neuroantigens myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) and T cell mitogen (PHA) in MS patients in relapse and remission, patients with other neurological disorders (OND) and normal healthy controls. MS patients in relapse exhibited significantly increased PBMC production of TNF-alpha spontaneously compared with MS remission and healthy controls and with MBP compared with MS remission. Patients in relapse had significantly increased spontaneous, PHA- and MBP-induced PBMC IL-1beta production compared with remission MS, and was increased compared (PHA only) with OND and healthy controls. In relapse there was also significantly increased PBMC IFN-gamma production (PHA only) compared with remission and a significantly lower production of biologically active TGF-beta1 (PHA only) compared with remission MS and OND. In contrast, MS patients in remission produced significantly less spontaneous and MBP-induced TNF-alpha, spontaneous, PHA- and MBP-induced IL-1beta and PHA-induced IFN-gamma together with increased production of biologically active TGF-beta1. MOG non-specifically increased PBMC TNF-alpha and IL-1beta production in all groups. Pro-inflammatory cytokines in corresponding plasma samples were undetectable whilst the concentration of biologically active TGF-beta1 was the reverse of ex vivo PBMC findings. The increase in biologically active TGF-beta1 production ex vivo in OND patients, despite active disease, compared with the low level in the MS relapse may indicate a regulatory defect in MS. We conclude that the balance between biologically active TGF-beta1 and the pro-inflammatory TNF-alpha, IL-1beta and IFN-gamma is dysregulated during MS relapse-remission and that normal counter-regulatory mechanisms during the relapse phase are defective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911279     DOI: 10.1080/0891693031000089427

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  14 in total

Review 1.  Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis.

Authors:  Hadi Atabati; Esmaeil Yazdanpanah; Hamed Mortazavi; Saeed Gharibian Bajestani; Amir Raoofi; Seyed-Alireza Esmaeili; Azad Khaledi; Ehsan Saburi; Jalil Tavakol Afshari; Thozhukat Sathyapalan; Abbas Shapouri Moghaddam; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Authors:  Helen Tremlett; Joel Oger
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

3.  Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients.

Authors:  Sarah A Imam; Mary K Guyton; Azizul Haque; Arthur Vandenbark; William R Tyor; Swapan K Ray; Naren L Banik
Journal:  J Neuroimmunol       Date:  2007-09-04       Impact factor: 3.478

Review 4.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

5.  Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis.

Authors:  D Pisa; R Alonso; F J Jiménez-Jiménez; L Carrasco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-16       Impact factor: 3.267

6.  TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis.

Authors:  Manuel Comabella; Cristina Romera; Montse Camiña; Hector Perkal; María A Moro; Juan C Leza; Ignacio Lizasoain; Mireia Castillo; Xavier Montalban
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

7.  Expression analysis of long non-coding RNAs and their target genes in multiple sclerosis patients.

Authors:  Maziar Ganji; Arezou Sayad; Mir Davood Omrani; Shahram Arsang-Jang; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  Neurol Sci       Date:  2019-01-24       Impact factor: 3.307

Review 8.  Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Francesco Girolamo; Cristiana Coppola; Domenico Ribatti; Maria Trojano
Journal:  Acta Neuropathol Commun       Date:  2014-07-22       Impact factor: 7.801

9.  Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone.

Authors:  Amy Perrin Ross; Aliza Ben-Zacharia; Colleen Harris; Jennifer Smrtka
Journal:  Front Neurol       Date:  2013-03-08       Impact factor: 4.003

10.  The Involvement of Calpain in CD4+ T Helper Cell Bias in Multple Sclerosis.

Authors:  Nicole Trager; Jonathan T Butler; Azizul Haque; Swapan K Ray; Craig Beeson; Naren L Banik
Journal:  J Clin Cell Immunol       Date:  2013-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.